{"symbol":"LLY","fiscalQuarter":"Q3-2018","reportDate":"2018-11-06","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q3-2018","postBrief":{"headline":"Eli Lilly Misses on EPS, Stock Down 3.85%","keyNumbers":[{"metric":"EPS","actual":"$1.39","expected":"N/A","surprise":"-2.03%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing investments in research and development.","They expressed confidence in long-term growth despite current challenges."],"summary":"Management remains focused on innovation and future product pipelines. They acknowledged the current market pressures but are optimistic about future opportunities."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Eli Lilly's earnings report showed a slight miss on EPS, which contributed to a 3.85% decline in stock price. Investors may be concerned about the lack of revenue details and forward guidance, leading to uncertainty in the stock's near-term performance. The company's focus on R&D suggests a long-term strategy, but immediate reactions reflect caution among investors.","metaDescription":"Eli Lilly (LLY) Q3 2018 earnings: EPS missed expectations. Stock down 3.85%. Full breakdown."}}